person · Reporting owner

BERGER FRANKLIN M

Disclosed activity across 10 companies

Tapewire entity: 35943
SEC CIK: 0001273885

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Atea Pharmaceuticals, Inc.AVIR · Entity 5580	Director	June 18, 2026	June 23, 2026
Atreca, Inc.BCEL · Entity 91940	Director	June 13, 2023	June 15, 2023
ESSA Pharma Inc.EPIX · Entity 15763	Director	October 09, 2025	October 15, 2025
Forte Biosciences, Inc.TOCA · Entity 9529	Director	October 04, 2019	October 05, 2019
IMMUNE DESIGN CORP.IMDZ · Entity 158527	Director	April 02, 2019	April 04, 2019
KINETA, INC./DEPTI · Entity 77778	Director	June 29, 2020	July 01, 2020
Rain Oncology Inc.RAIN · Entity 94695	Director	January 26, 2024	January 26, 2024
Retension Pharmaceuticals, Inc.RTSN · Entity 184313	Director	October 13, 2026	October 13, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Atea Pharmaceuticals, Inc.

Report date June 18, 2026 · Filed June 23, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	536,097	Reported balance After 2026-06-18 transaction · row 1 1 source row Row 1 · 2026-06-18 · Exercise / conversion · Acquired 29,600 · Balance 536,097 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-06-18 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-18 · Exercise / conversion · Disposed 29,600 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2: The RSUs vested in full on June 18, 2026.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	26,700	Reported balance After 2026-06-18 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-06-18 · Grant · Acquired 26,700 · Balance 26,700 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3: The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after June 18, 2026 or (ii) June 18, 2027, in each case, subject to the Reporting Person's continued service through the applicable vesting date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.36 · Expires 2036-06-17	Direct	37,700	Reported balance After 2026-06-18 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-06-18 · Grant · Acquired 37,700 · Balance 37,700 F4: The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 18, 2026, such that the option shall be fully vested on June 18, 2027, subject to the Reporting Person's continued service through each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F2: The RSUs vested in full on June 18, 2026.

F3: The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after June 18, 2026 or (ii) June 18, 2027, in each case, subject to the Reporting Person's continued service through the applicable vesting date.

F4: The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 18, 2026, such that the option shall be fully vested on June 18, 2027, subject to the Reporting Person's continued service through each such vesting date.

Atreca, Inc.

Report date June 13, 2023 · Filed June 15, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.18 · Expires 2023-06-12	Direct	12,000	Reported balance After 2023-06-13 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-06-13 · Grant · Acquired 12,000 · Balance 12,000 F1: The option vests upon the earlier of the one-year anniversary of the date of grant or the day prior to the next Annual Meeting of Stockholders occurring after the grant date, subject to the non-employee director's continuous service on each applicable vesting date. All unvested options will vest in full immediately prior to a change in control (as defined in the Company's 2019 Equity Incentive Plan), subject to the non-employee director's continuous service as of immediately prior to the closing of such change in control.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests upon the earlier of the one-year anniversary of the date of grant or the day prior to the next Annual Meeting of Stockholders occurring after the grant date, subject to the non-employee director's continuous service on each applicable vesting date. All unvested options will vest in full immediately prior to a change in control (as defined in the Company's 2019 Equity Incentive Plan), subject to the non-employee director's continuous service as of immediately prior to the closing of such change in control.

ESSA Pharma Inc.

Report date October 09, 2025 · Filed October 15, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common SharesSEC Table I · non-derivative	Direct	0	Reported balance After 2025-10-09 transaction · row 1 1 source row Row 1 · 2025-10-09 · Disposition to issuer · Disposed 784,404 · Balance 0 F1: On October 9, 2025, pursuant to that certain Business Combination Agreement, dated July 13, 2025 (as amended by the Amendment Agreement, dated September 23, 2025, the "Agreement"), by and among the Issuer, XenoTherapeutics, Inc., Xeno Acquisition Corp. ("Purchaser") and XOMA Royalty Corporation, the Purchaser acquired all of the issued and outstanding common shares of the Issuer for (i) cash consideration of approximately US$0.12 per share and (ii) one contingent value right ("CVR") for each common share entitling its holder to receive up to approximately US$0.14 per CVR and payable within specified periods following the close of the transactions contemplated by the Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: On October 9, 2025, pursuant to that certain Business Combination Agreement, dated July 13, 2025 (as amended by the Amendment Agreement, dated September 23, 2025, the "Agreement"), by and among the Issuer, XenoTherapeutics, Inc., Xeno Acquisition Corp. ("Purchaser") and XOMA Royalty Corporation, the Purchaser acquired all of the issued and outstanding common shares of the Issuer for (i) cash consideration of approximately US$0.12 per share and (ii) one contingent value right ("CVR") for each common share entitling its holder to receive up to approximately US$0.14 per CVR and payable within specified periods following the close of the transactions contemplated by the Agreement.

Forte Biosciences, Inc.

Report date October 04, 2019 · Filed October 05, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.64 · Expires 2029-10-03	Direct	7,500	Reported balance After 2019-10-04 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-10-04 · Grant · Acquired 7,500 · Balance 7,500 F1: The shares vest in a series of twelve (12) successive equal monthly installments measured from October 3, 2019.

Filing footnotes · ownership attribution and instrument terms

F1: The shares vest in a series of twelve (12) successive equal monthly installments measured from October 3, 2019.

IMMUNE DESIGN CORP.

Report date April 02, 2019 · Filed April 04, 2019

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2019-04-02 transaction · row 1 1 source row Row 1 · 2019-04-02 · Disposition to issuer · Disposed 75,000 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated February 20, 2019, by and among the Immune Design Corp. (the "Issuer"), Merck Sharp & Dohme Corp., a New Jersey corporation ("Parent") and Cascade Merger Sub Inc., a Delaware corporation ("Purchaser"), on April 2, 2019, Purchaser merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, the Issuer's common stock were cancelled and converted into the right to receive $5.85 in cash per share, less any required withholding, subject to the terms and conditions of the Merger Agreement ("Merger Consideration").
Stock Option (Rt to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.60	Direct	Reported balance After 2019-04-02 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-04-02 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share. F3: Not Applicable.
Stock Option (Rt to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.05	Direct	Reported balance After 2019-04-02 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-04-02 · Disposition to issuer · Disposed 12,500 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share. F3: Not Applicable.
Stock Option (Rt to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.31	Direct	Reported balance After 2019-04-02 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2019-04-02 · Disposition to issuer · Disposed 12,500 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share. F3: Not Applicable.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated February 20, 2019, by and among the Immune Design Corp. (the "Issuer"), Merck Sharp & Dohme Corp., a New Jersey corporation ("Parent") and Cascade Merger Sub Inc., a Delaware corporation ("Purchaser"), on April 2, 2019, Purchaser merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, the Issuer's common stock were cancelled and converted into the right to receive $5.85 in cash per share, less any required withholding, subject to the terms and conditions of the Merger Agreement ("Merger Consideration").

F2: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share.

F3: Not Applicable.

KINETA, INC./DE

Report date June 29, 2020 · Filed July 01, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.39 · Expires 2030-06-29	Direct	17,400	Reported balance After 2020-06-29 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-06-29 · Grant · Acquired 17,400 · Balance 17,400 F1: These securities shall vest and become exercisable in equal quarterly installments starting on September 29, 2020 until the option is fully vested and exercisable on June 29, 2021, subject to the Reporting Person continuing to provide services to the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: These securities shall vest and become exercisable in equal quarterly installments starting on September 29, 2020 until the option is fully vested and exercisable on June 29, 2021, subject to the Reporting Person continuing to provide services to the Issuer.

Rain Oncology Inc.

Report date January 26, 2024 · Filed January 26, 2024

Security / award	Ownership account	Disclosure context
Common Stock, par value $0.001 per shareSEC Table I · non-derivative	Direct	Reported balance After 2024-01-26 transaction · row 1 1 source row Row 1 · 2024-01-26 · Other · Disposed 1,005,207 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $1.16 in cash without interest, plus (ii) one contingent value right.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.21	Direct	Reported balance After 2024-01-26 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-01-26 · Disposition to issuer · Disposed 35,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.91	Direct	Reported balance After 2024-01-26 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-01-26 · Disposition to issuer · Disposed 24,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.44	Direct	Reported balance After 2024-01-26 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-01-26 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $1.16 in cash without interest, plus (ii) one contingent value right.

F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.

Retension Pharmaceuticals, Inc.

Report date October 13, 2026 · Filed October 13, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	12,517	Reported balance After 2026-10-13 transaction · row 1 1 source row Row 1 · 2026-10-13 · Conversion · Acquired 12,517 · Balance 12,517 F1: Each share of Series B Convertible Preferred Stock (the "Series B Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had no expiration date.
Common StockSEC Table I · non-derivative	IndirectBy FMB Research	10,000	Reported balance After 2026-10-13 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2026-10-13 · Purchase · Acquired 10,000 · Balance 10,000
Series B Convertible Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-10-13 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-10-13 · Conversion · Disposed 12,517 · Balance 0 F1: Each share of Series B Convertible Preferred Stock (the "Series B Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Series B Convertible Preferred Stock (the "Series B Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had no expiration date.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

FIVE PRIME THERAPEUTICS, INC.

Report date April 16, 2021 · Filed April 19, 2021

Section 16 reporting ended · disclosed 2021-04-19. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2021-04-16 transaction · row 1 1 source row Row 1 · 2021-04-16 · Disposition to issuer · Disposed 5,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, each issued and outstanding share of common stock of the Company, par value $0.001 per share ("Common Stock"), was converted into the right to receive $38.00 per share (the "Offer Price") in cash, without interest, minus any applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.15	Direct	Reported balance After 2021-04-16 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-04-16 · Disposition to issuer · Disposed 12,500 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of Common Stock granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per share under such option. F3: Not applicable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.80	Direct	Reported balance After 2021-04-16 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-04-16 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of Common Stock granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per share under such option. F3: Not applicable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.27	Direct	Reported balance After 2021-04-16 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-04-16 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of Common Stock granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per share under such option. F3: Not applicable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.09	Direct	Reported balance After 2021-04-16 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2021-04-16 · Disposition to issuer · Disposed 15,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of Common Stock granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per share under such option. F3: Not applicable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.14	Direct	Reported balance After 2021-04-16 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2021-04-16 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of Common Stock granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per share under such option. F3: Not applicable.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, each issued and outstanding share of common stock of the Company, par value $0.001 per share ("Common Stock"), was converted into the right to receive $38.00 per share (the "Offer Price") in cash, without interest, minus any applicable withholding taxes.

F2: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of Common Stock granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per share under such option.

F3: Not applicable.

Kezar Life Sciences, Inc.

Report date May 11, 2026 · Filed May 11, 2026

Section 16 reporting ended · disclosed 2026-05-11. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2026-05-11 transaction · row 1 1 source row Row 1 · 2026-05-11 · Other · Disposed 89,069 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of March 30, 2026 (the "Merger Agreement"), by and among the Issuer, Aurinia Pharma U.S., Inc. ("Parent") and Parent's direct wholly owned subsidiary, Aurinia Merger Sub, Inc., ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $6.955 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration"); plus (ii) one non-tradable contingent value right (each, a "CVR"), which represents the right to receive certain payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "CVR Agreement") F2: (continued from footnote 1) without interest and less any applicable tax withholding, upon the achievement of specified milestones in accordance with the terms and subject to the conditions of a CVR Agreement with Broadridge Corporate Issuer Solutions, LLC, as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of May 11, 2026, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the "Effective Time").
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.40 · Expires 2033-06-14	Direct	Reported balance After 2026-05-11 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-05-11 · Disposition to issuer · Disposed 3,500 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than the Cash Amount (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist at the Effective Time, and no consideration was delivered in exchange for such Out-of-the-Money Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.70 · Expires 2034-06-19	Direct	Reported balance After 2026-05-11 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-05-11 · Disposition to issuer · Disposed 5,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, each Company Stock Option that had a per share exercise price less than the Cash Amount (an "In-the-Money Option") was automatically cancelled and converted at the Effective Time into the right to receive (A) an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share underlying such Company Stock Option at the Effective Time by (y) the number of shares underlying such In-the-Money Option, subject to the terms and conditions specified in the Merger Agreement and (B) one CVR in respect of each share underlying such In-the-Money Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.46 · Expires 2035-06-17	Direct	Reported balance After 2026-05-11 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-05-11 · Disposition to issuer · Disposed 5,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, each Company Stock Option that had a per share exercise price less than the Cash Amount (an "In-the-Money Option") was automatically cancelled and converted at the Effective Time into the right to receive (A) an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share underlying such Company Stock Option at the Effective Time by (y) the number of shares underlying such In-the-Money Option, subject to the terms and conditions specified in the Merger Agreement and (B) one CVR in respect of each share underlying such In-the-Money Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.80 · Expires 2031-06-27	Direct	Reported balance After 2026-05-11 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-05-11 · Disposition to issuer · Disposed 2,600 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than the Cash Amount (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist at the Effective Time, and no consideration was delivered in exchange for such Out-of-the-Money Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.80 · Expires 2032-06-15	Direct	Reported balance After 2026-05-11 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-05-11 · Disposition to issuer · Disposed 2,600 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than the Cash Amount (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist at the Effective Time, and no consideration was delivered in exchange for such Out-of-the-Money Option.

Filing footnotes · ownership attribution and instrument terms

F1: In connection with the terms of an Agreement and Plan of Merger, dated as of March 30, 2026 (the "Merger Agreement"), by and among the Issuer, Aurinia Pharma U.S., Inc. ("Parent") and Parent's direct wholly owned subsidiary, Aurinia Merger Sub, Inc., ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $6.955 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration"); plus (ii) one non-tradable contingent value right (each, a "CVR"), which represents the right to receive certain payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "CVR Agreement")

F2: (continued from footnote 1) without interest and less any applicable tax withholding, upon the achievement of specified milestones in accordance with the terms and subject to the conditions of a CVR Agreement with Broadridge Corporate Issuer Solutions, LLC, as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of May 11, 2026, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the "Effective Time").

F3: Pursuant to the terms of the Merger Agreement, each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than the Cash Amount (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist at the Effective Time, and no consideration was delivered in exchange for such Out-of-the-Money Option.

F4: Pursuant to the terms of the Merger Agreement, each Company Stock Option that had a per share exercise price less than the Cash Amount (an "In-the-Money Option") was automatically cancelled and converted at the Effective Time into the right to receive (A) an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share underlying such Company Stock Option at the Effective Time by (y) the number of shares underlying such In-the-Money Option, subject to the terms and conditions specified in the Merger Agreement and (B) one CVR in respect of each share underlying such In-the-Money Option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
October 13, 2026 Filed Oct 13, 2026 22:10 UTC	Retension Pharmaceuticals, Inc. RTSN · Entity 184313	ConversionSeries B Convertible Preferred Stock · Derivative	12,517	Not disclosed	Not disclosed	Disclosure SEC source: 0001213900-26-109155 · ownership.xml · derivative · entry 3 BERGER FRANKLIN M · CIK 0001273885 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,517 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B Convertible Preferred Stock (the "Series B Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had no expiration date. F1 · price: Each share of Series B Convertible Preferred Stock (the "Series B Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series B Convertible Preferred Stock (the "Series B Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series B Convertible Preferred Stock (the "Series B Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had no expiration date. Read SEC document
October 13, 2026 Filed Oct 13, 2026 22:10 UTC	Retension Pharmaceuticals, Inc. RTSN · Entity 184313	PurchaseCommon Stock	10,000	$12.00	$120,000.00	Disclosure SEC source: 0001213900-26-109155 · ownership.xml · nonDerivative · entry 2 BERGER FRANKLIN M · CIK 0001273885 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By FMB Research Disclosed balance after: 10,000 Read SEC document
October 13, 2026 Filed Oct 13, 2026 22:10 UTC	Retension Pharmaceuticals, Inc. RTSN · Entity 184313	ConversionCommon Stock	12,517	Not disclosed	Not disclosed	Disclosure SEC source: 0001213900-26-109155 · ownership.xml · nonDerivative · entry 1 BERGER FRANKLIN M · CIK 0001273885 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,517 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series B Convertible Preferred Stock (the "Series B Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had no expiration date. Read SEC document
October 08, 2026 Filed Oct 9, 2026 01:38 UTC	Retension Pharmaceuticals, Inc. RTSN · Entity 184313	GrantStock Option (right to buy) · Derivative	5,636	$0.00 Strike: $12.00	$0.00	Disclosure SEC source: 0001213900-26-108188 · ownership.xml · derivative · entry 1 BERGER FRANKLIN M · CIK 0001273885 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,636 Underlying: Common Stock · 5,636 shares Expires 2036-10-08 F1 · security: Option award granted pursuant to the Issuer's 2026 Equity Incentive Plan. Twenty-five percent of the stock option vests on the first anniversary of the date of grant, with the remaining stock options vesting in 12 quarterly increments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date. F1 · derivative.exercise_date: Option award granted pursuant to the Issuer's 2026 Equity Incentive Plan. Twenty-five percent of the stock option vests on the first anniversary of the date of grant, with the remaining stock options vesting in 12 quarterly increments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document
June 18, 2026 Filed Jun 23, 2026 21:00 UTC	Atea Pharmaceuticals, Inc. AVIR · Entity 5580	GrantStock Option (Right to Buy) · Derivative	37,700	$0.00 Strike: $4.36	$0.00	Disclosure SEC source: 0001193125-26-279726 · ownership.xml · derivative · entry 4 BERGER FRANKLIN M · CIK 0001273885 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,700 Underlying: Common Stock · 37,700 shares Expires 2036-06-17 F4 · derivative.exercise_date: The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 18, 2026, such that the option shall be fully vested on June 18, 2027, subject to the Reporting Person's continued service through each such vesting date. Read SEC document
June 18, 2026 Filed Jun 23, 2026 21:00 UTC	Atea Pharmaceuticals, Inc. AVIR · Entity 5580	GrantRestricted Stock Units · Derivative	26,700	$0.00	$0.00	Disclosure SEC source: 0001193125-26-279726 · ownership.xml · derivative · entry 3 BERGER FRANKLIN M · CIK 0001273885 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,700 Underlying: Common Stock · 26,700 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after June 18, 2026 or (ii) June 18, 2027, in each case, subject to the Reporting Person's continued service through the applicable vesting date. F3 · derivative.expiration_date: The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after June 18, 2026 or (ii) June 18, 2027, in each case, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document
June 18, 2026 Filed Jun 23, 2026 21:00 UTC	Atea Pharmaceuticals, Inc. AVIR · Entity 5580	Exercise / conversionRestricted Stock Units · Derivative	29,600	$0.00	$0.00	Disclosure SEC source: 0001193125-26-279726 · ownership.xml · derivative · entry 2 BERGER FRANKLIN M · CIK 0001273885 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSUs vested in full on June 18, 2026. F2 · derivative.expiration_date: The RSUs vested in full on June 18, 2026. Read SEC document
June 18, 2026 Filed Jun 23, 2026 21:00 UTC	Atea Pharmaceuticals, Inc. AVIR · Entity 5580	Exercise / conversionCommon Stock	29,600	$0.00	$0.00	Disclosure SEC source: 0001193125-26-279726 · ownership.xml · nonDerivative · entry 1 BERGER FRANKLIN M · CIK 0001273885 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 536,097 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
May 11, 2026 Filed May 11, 2026 20:30 UTC	Kezar Life Sciences, Inc. KZR · Entity 12111	Disposition to issuerStock Option (right to buy) · Derivative	2,600	$0.00 Strike: $22.80	$0.00	Disclosure SEC source: 0001273885-26-000002 · form4-05112026_040505.xml · derivative · entry 6 BERGER FRANKLIN M · CIK 0001273885 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,600 shares Expires 2032-06-15 F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than the Cash Amount (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist at the Effective Time, and no consideration was delivered in exchange for such Out-of-the-Money Option. Read SEC document
May 11, 2026 Filed May 11, 2026 20:30 UTC	Kezar Life Sciences, Inc. KZR · Entity 12111	Disposition to issuerStock Option (right to buy) · Derivative	2,600	$0.00 Strike: $22.80	$0.00	Disclosure SEC source: 0001273885-26-000002 · form4-05112026_040505.xml · derivative · entry 5 BERGER FRANKLIN M · CIK 0001273885 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,600 shares Expires 2031-06-27 F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than the Cash Amount (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist at the Effective Time, and no consideration was delivered in exchange for such Out-of-the-Money Option. Read SEC document
May 11, 2026 Filed May 11, 2026 20:30 UTC	Kezar Life Sciences, Inc. KZR · Entity 12111	Disposition to issuerStock Option (right to buy) · Derivative	5,000	$0.00 Strike: $4.46	$0.00	Disclosure SEC source: 0001273885-26-000002 · form4-05112026_040505.xml · derivative · entry 4 BERGER FRANKLIN M · CIK 0001273885 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2035-06-17 F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each Company Stock Option that had a per share exercise price less than the Cash Amount (an "In-the-Money Option") was automatically cancelled and converted at the Effective Time into the right to receive (A) an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share underlying such Company Stock Option at the Effective Time by (y) the number of shares underlying such In-the-Money Option, subject to the terms and conditions specified in the Merger Agreement and (B) one CVR in respect of each share underlying such In-the-Money Option. Read SEC document
May 11, 2026 Filed May 11, 2026 20:30 UTC	Kezar Life Sciences, Inc. KZR · Entity 12111	Disposition to issuerStock Option (right to buy) · Derivative	5,000	$0.00 Strike: $6.70	$0.00	Disclosure SEC source: 0001273885-26-000002 · form4-05112026_040505.xml · derivative · entry 3 BERGER FRANKLIN M · CIK 0001273885 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2034-06-19 F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each Company Stock Option that had a per share exercise price less than the Cash Amount (an "In-the-Money Option") was automatically cancelled and converted at the Effective Time into the right to receive (A) an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share underlying such Company Stock Option at the Effective Time by (y) the number of shares underlying such In-the-Money Option, subject to the terms and conditions specified in the Merger Agreement and (B) one CVR in respect of each share underlying such In-the-Money Option. Read SEC document
May 11, 2026 Filed May 11, 2026 20:30 UTC	Kezar Life Sciences, Inc. KZR · Entity 12111	Disposition to issuerStock Option (right to buy) · Derivative	3,500	$0.00 Strike: $26.40	$0.00	Disclosure SEC source: 0001273885-26-000002 · form4-05112026_040505.xml · derivative · entry 2 BERGER FRANKLIN M · CIK 0001273885 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,500 shares Expires 2033-06-14 F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than the Cash Amount (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist at the Effective Time, and no consideration was delivered in exchange for such Out-of-the-Money Option. Read SEC document
May 11, 2026 Filed May 11, 2026 20:30 UTC	Kezar Life Sciences, Inc. KZR · Entity 12111	OtherCommon Stock	89,069	Not disclosed	Not disclosed	Disclosure SEC source: 0001273885-26-000002 · form4-05112026_040505.xml · nonDerivative · entry 1 BERGER FRANKLIN M · CIK 0001273885 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: In connection with the terms of an Agreement and Plan of Merger, dated as of March 30, 2026 (the "Merger Agreement"), by and among the Issuer, Aurinia Pharma U.S., Inc. ("Parent") and Parent's direct wholly owned subsidiary, Aurinia Merger Sub, Inc., ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $6.955 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration"); plus (ii) one non-tradable contingent value right (each, a "CVR"), which represents the right to receive certain payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "CVR Agreement") F2 · kind: (continued from footnote 1) without interest and less any applicable tax withholding, upon the achievement of specified milestones in accordance with the terms and subject to the conditions of a CVR Agreement with Broadridge Corporate Issuer Solutions, LLC, as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of May 11, 2026, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the "Effective Time"). F1 · price: In connection with the terms of an Agreement and Plan of Merger, dated as of March 30, 2026 (the "Merger Agreement"), by and among the Issuer, Aurinia Pharma U.S., Inc. ("Parent") and Parent's direct wholly owned subsidiary, Aurinia Merger Sub, Inc., ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $6.955 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration"); plus (ii) one non-tradable contingent value right (each, a "CVR"), which represents the right to receive certain payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "CVR Agreement") Read SEC document
October 09, 2025 Filed Oct 15, 2025 12:01 UTC	ESSA Pharma Inc. EPIX · Entity 15763	Disposition to issuerCommon Shares	784,404	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-25-099655 · tm2528208-5_4seq.xml · nonDerivative · entry 1 BERGER FRANKLIN M · CIK 0001273885 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: On October 9, 2025, pursuant to that certain Business Combination Agreement, dated July 13, 2025 (as amended by the Amendment Agreement, dated September 23, 2025, the "Agreement"), by and among the Issuer, XenoTherapeutics, Inc., Xeno Acquisition Corp. ("Purchaser") and XOMA Royalty Corporation, the Purchaser acquired all of the issued and outstanding common shares of the Issuer for (i) cash consideration of approximately US$0.12 per share and (ii) one contingent value right ("CVR") for each common share entitling its holder to receive up to approximately US$0.14 per CVR and payable within specified periods following the close of the transactions contemplated by the Agreement. Read SEC document
June 20, 2025 Filed Jun 24, 2025 22:05 UTC	Atea Pharmaceuticals, Inc. AVIR · Entity 5580	Exercise / conversionRestricted Stock Units · Derivative	29,600	$0.00	$0.00	Disclosure SEC source: 0000950170-25-089606 · ownership.xml · derivative · entry 4 BERGER FRANKLIN M · CIK 0001273885 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: The restricted stock units vested in full on June 20, 2025. F4 · derivative.expiration_date: The restricted stock units vested in full on June 20, 2025. Read SEC document
June 20, 2025 Filed Jun 24, 2025 22:05 UTC	Atea Pharmaceuticals, Inc. AVIR · Entity 5580	GrantStock Option (Right to Buy) · Derivative	41,200	$0.00 Strike: $3.25	$0.00	Disclosure SEC source: 0000950170-25-089606 · ownership.xml · derivative · entry 3 BERGER FRANKLIN M · CIK 0001273885 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,200 Underlying: Common Stock · 41,200 shares Expires 2035-06-19 F3 · derivative.exercise_date: The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 20, 2025, such that the option shall be fully vested on the first anniversary of the date of grant, subject to the Reporting Person's continued service through each such vesting date. Read SEC document
June 20, 2025 Filed Jun 24, 2025 22:05 UTC	Atea Pharmaceuticals, Inc. AVIR · Entity 5580	GrantRestricted Stock Units · Derivative	29,600	$0.00	$0.00	Disclosure SEC source: 0000950170-25-089606 · ownership.xml · derivative · entry 2 BERGER FRANKLIN M · CIK 0001273885 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,600 Underlying: Common Stock · 29,600 shares Expires not disclosed F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: The restricted stock units vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date. F2 · derivative.expiration_date: The restricted stock units vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document
June 20, 2025 Filed Jun 24, 2025 22:05 UTC	Atea Pharmaceuticals, Inc. AVIR · Entity 5580	Exercise / conversionCommon Stock	29,600	$0.00	$0.00	Disclosure SEC source: 0000950170-25-089606 · ownership.xml · nonDerivative · entry 1 BERGER FRANKLIN M · CIK 0001273885 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 506,497 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
June 18, 2025 Filed Jun 23, 2025 21:00 UTC	Kezar Life Sciences, Inc. KZR · Entity 12111	GrantStock Option (right to buy) · Derivative	5,000	$0.00 Strike: $4.46	$0.00	Disclosure SEC source: 0001415889-25-017966 · form4-06232025_050604.xml · derivative · entry 1 BERGER FRANKLIN M · CIK 0001273885 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2035-06-17 F1 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option shall vest on 6/18/2026, subject to Reporting Person continuing to provide service through such date. Read SEC document
January 16, 2025 Filed Jan 17, 2025 19:30 UTC Amendment	Atea Pharmaceuticals, Inc. AVIR · Entity 5580	PurchaseCommon Stock	10,000	$3.36	$33,614.00	Disclosure SEC source: 0000950170-25-006589 · ownership.xml · nonDerivative · entry 2 BERGER FRANKLIN M · CIK 0001273885 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 476,897 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.32 to $3.405. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F1 · acquired: This Form 4/A has been filed solely to change the code reported in Column 4 of Table I of the Reporting Person's Form 4 filed on January 17, 2025, which had inadvertently noted a "D" instead of "A" to reflect an acquisition of the common stock of Atea Pharmaceuticals, Inc. (the "Company"), due to an administrative error. Read SEC document
January 16, 2025 Filed Jan 17, 2025 13:03 UTC	Atea Pharmaceuticals, Inc. AVIR · Entity 5580	PurchaseCommon Stock	10,000	$3.36	$33,614.00	Disclosure SEC source: 0000950170-25-006489 · ownership.xml · nonDerivative · entry 2 BERGER FRANKLIN M · CIK 0001273885 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 476,897 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.32 to $3.405. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
January 15, 2025 Filed Jan 17, 2025 19:30 UTC Amendment	Atea Pharmaceuticals, Inc. AVIR · Entity 5580	PurchaseCommon Stock	15,000	$3.19	$47,884.50	Disclosure SEC source: 0000950170-25-006589 · ownership.xml · nonDerivative · entry 1 BERGER FRANKLIN M · CIK 0001273885 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 466,897 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.165 to $3.21. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F1 · acquired: This Form 4/A has been filed solely to change the code reported in Column 4 of Table I of the Reporting Person's Form 4 filed on January 17, 2025, which had inadvertently noted a "D" instead of "A" to reflect an acquisition of the common stock of Atea Pharmaceuticals, Inc. (the "Company"), due to an administrative error. Read SEC document
January 15, 2025 Filed Jan 17, 2025 13:03 UTC	Atea Pharmaceuticals, Inc. AVIR · Entity 5580	PurchaseCommon Stock	15,000	$3.19	$47,884.50	Disclosure SEC source: 0000950170-25-006489 · ownership.xml · nonDerivative · entry 1 BERGER FRANKLIN M · CIK 0001273885 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 466,897 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.165 to $3.21. The Reporting Person undertakes to provide Atea Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
December 10, 2024 Filed Dec 12, 2024 23:00 UTC	Atea Pharmaceuticals, Inc. AVIR · Entity 5580	SaleCommon Stock	359,606	$2.85	$1,023,474.64	Disclosure SEC source: 0000950170-24-135930 · ownership.xml · nonDerivative · entry 1 BERGER FRANKLIN M · CIK 0001273885 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 451,897 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.75 to $2.955. The Reporting Person undertakes to provide Atea Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
June 21, 2024 Filed Jun 21, 2024 22:08 UTC	Atea Pharmaceuticals, Inc. AVIR · Entity 5580	GrantStock Option (Right to Buy) · Derivative	41,200	$0.00 Strike: $3.44	$0.00	Disclosure SEC source: 0000950170-24-076394 · ownership.xml · derivative · entry 2 BERGER FRANKLIN M · CIK 0001273885 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,200 Underlying: Common Stock · 41,200 shares Expires 2034-06-20 F3 · derivative.exercise_date: The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 21, 2024, such that the option shall be fully vested on the first anniversary of the date of grant, subject to the Reporting Person's continued service through each such vesting date. Read SEC document
June 21, 2024 Filed Jun 21, 2024 22:08 UTC	Atea Pharmaceuticals, Inc. AVIR · Entity 5580	GrantRestricted Stock Units · Derivative	29,600	$0.00	$0.00	Disclosure SEC source: 0000950170-24-076394 · ownership.xml · derivative · entry 1 BERGER FRANKLIN M · CIK 0001273885 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,600 Underlying: Common Stock · 29,600 shares Expires not disclosed F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: The restricted stock units vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date. F2 · derivative.expiration_date: The restricted stock units vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document
June 20, 2024 Filed Jun 21, 2024 20:20 UTC	Kezar Life Sciences, Inc. KZR · Entity 12111	GrantStock Option (right to buy) · Derivative	50,000	$0.00 Strike: $0.67	$0.00	Disclosure SEC source: 0001415889-24-017836 · form4-06212024_040602.xml · derivative · entry 1 BERGER FRANKLIN M · CIK 0001273885 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-06-19 F1 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option shall vest on 6/20/2025, subject to Reporting Person continuing to provide service through such date. Read SEC document
June 16, 2024 Filed Jun 18, 2024 21:00 UTC	Atea Pharmaceuticals, Inc. AVIR · Entity 5580	Exercise / conversionRestricted Stock Units · Derivative	33,150	$0.00	$0.00	Disclosure SEC source: 0000950170-24-074987 · ownership.xml · derivative · entry 2 BERGER FRANKLIN M · CIK 0001273885 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,150 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: The restricted stock units are fully vested. F3 · derivative.expiration_date: The restricted stock units do not have an expiration date. Read SEC document
June 16, 2024 Filed Jun 18, 2024 21:00 UTC	Atea Pharmaceuticals, Inc. AVIR · Entity 5580	Exercise / conversionCommon Stock	33,150	$0.00	$0.00	Disclosure SEC source: 0000950170-24-074987 · ownership.xml · nonDerivative · entry 1 BERGER FRANKLIN M · CIK 0001273885 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 811,503 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
March 25, 2024 Filed Mar 28, 2024 12:32 UTC	ESSA Pharma Inc. EPIX · Entity 15763	GrantOptions · Derivative	50,000	$0.00 Strike: $9.04	$0.00	Disclosure SEC source: 0000950172-24-000133 · form4.xml · derivative · entry 1 BERGER FRANKLIN M · CIK 0001273885 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Shares · 50,000 shares Expires 2034-03-25 Read SEC document
January 26, 2024 Filed Jan 26, 2024 16:39 UTC	Rain Oncology Inc. RAIN · Entity 94695	Disposition to issuerStock Option (Right to Buy) · Derivative	20,000	Not disclosed Strike: $2.44	Not disclosed	Disclosure SEC source: 0001999371-24-000962 · ownership.xml · derivative · entry 4 BERGER FRANKLIN M · CIK 0001273885 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. Read SEC document
January 26, 2024 Filed Jan 26, 2024 16:39 UTC	Rain Oncology Inc. RAIN · Entity 94695	Disposition to issuerStock Option (Right to Buy) · Derivative	24,000	Not disclosed Strike: $15.91	Not disclosed	Disclosure SEC source: 0001999371-24-000962 · ownership.xml · derivative · entry 3 BERGER FRANKLIN M · CIK 0001273885 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. Read SEC document
January 26, 2024 Filed Jan 26, 2024 16:39 UTC	Rain Oncology Inc. RAIN · Entity 94695	Disposition to issuerStock Option (Right to Buy) · Derivative	35,000	Not disclosed Strike: $1.21	Not disclosed	Disclosure SEC source: 0001999371-24-000962 · ownership.xml · derivative · entry 2 BERGER FRANKLIN M · CIK 0001273885 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. Read SEC document
January 26, 2024 Filed Jan 26, 2024 16:39 UTC	Rain Oncology Inc. RAIN · Entity 94695	OtherCommon Stock, par value $0.001 per share	1,005,207	Not disclosed	Not disclosed	Disclosure SEC source: 0001999371-24-000962 · ownership.xml · nonDerivative · entry 1 BERGER FRANKLIN M · CIK 0001273885 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $1.16 in cash without interest, plus (ii) one contingent value right. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $1.16 in cash without interest, plus (ii) one contingent value right. F1 · acquired: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $1.16 in cash without interest, plus (ii) one contingent value right. Read SEC document
November 21, 2023 Filed Nov 22, 2023 18:22 UTC	ESSA Pharma Inc. EPIX · Entity 15763	PurchaseCommon Shares	23,259	$5.73	$133,274.07	Disclosure SEC source: 0000950170-23-065921 · ownership.xml · nonDerivative · entry 1 BERGER FRANKLIN M · CIK 0001273885 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 784,404 Read SEC document
November 03, 2023 Filed Nov 16, 2023 17:45 UTC	ESSA Pharma Inc. EPIX · Entity 15763	PurchaseCommon Stock	16,471	$5.99	$98,661.29	Disclosure SEC source: 0000950170-23-064584 · ownership.xml · nonDerivative · entry 2 BERGER FRANKLIN M · CIK 0001273885 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 760,875 Read SEC document
November 02, 2023 Filed Nov 16, 2023 17:45 UTC	ESSA Pharma Inc. EPIX · Entity 15763	PurchaseCommon Stock	60,000	$5.35	$321,000.00	Disclosure SEC source: 0000950170-23-064584 · ownership.xml · nonDerivative · entry 1 BERGER FRANKLIN M · CIK 0001273885 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 744,404 Read SEC document
August 09, 2023 Filed Aug 11, 2023 21:14 UTC	Rain Oncology Inc. RAIN · Entity 94695	GrantStock Option (Right to Buy) · Derivative	35,000	$0.00 Strike: $1.21	$0.00	Disclosure SEC source: 0001104659-23-090704 · tm2323614-8_4seq1.xml · derivative · entry 1 BERGER FRANKLIN M · CIK 0001273885 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2033-08-09 F1 · derivative.exercise_date: This option represents a right to purchase a total of 35,000 shares of the Issuer's common stock, which will vest in full on the date of the 2024 Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service to the Issuer. Read SEC document
July 24, 2023 Filed Jul 26, 2023 20:56 UTC	Kezar Life Sciences, Inc. KZR · Entity 12111	GrantStock Option (Right to Buy) · Derivative	26,000	Not disclosed Strike: $2.28	Not disclosed	Disclosure SEC source: 0001209191-23-043423 · doc4.xml · derivative · entry 4 BERGER FRANKLIN M · CIK 0001273885 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2032-06-15 F2 · price: On July 24, 2023, the option originally granted to the Reporting Person was amended to reduce the exercise price to $2.28 per share. All of the other terms of the option remain unchanged. F1 · derivative.exercise_date: Fully vested and exercisable. Read SEC document
July 24, 2023 Filed Jul 26, 2023 20:56 UTC	Kezar Life Sciences, Inc. KZR · Entity 12111	Disposition to issuerStock Option (Right to Buy) · Derivative	26,000	Not disclosed Strike: $4.80	Not disclosed	Disclosure SEC source: 0001209191-23-043423 · doc4.xml · derivative · entry 3 BERGER FRANKLIN M · CIK 0001273885 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,000 shares Expires 2032-06-15 F2 · price: On July 24, 2023, the option originally granted to the Reporting Person was amended to reduce the exercise price to $2.28 per share. All of the other terms of the option remain unchanged. F1 · derivative.exercise_date: Fully vested and exercisable. Read SEC document
July 24, 2023 Filed Jul 26, 2023 20:56 UTC	Kezar Life Sciences, Inc. KZR · Entity 12111	GrantStock Option (Right to Buy) · Derivative	26,000	Not disclosed Strike: $2.28	Not disclosed	Disclosure SEC source: 0001209191-23-043423 · doc4.xml · derivative · entry 2 BERGER FRANKLIN M · CIK 0001273885 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2031-06-27 F2 · price: On July 24, 2023, the option originally granted to the Reporting Person was amended to reduce the exercise price to $2.28 per share. All of the other terms of the option remain unchanged. F1 · derivative.exercise_date: Fully vested and exercisable. Read SEC document
July 24, 2023 Filed Jul 26, 2023 20:56 UTC	Kezar Life Sciences, Inc. KZR · Entity 12111	Disposition to issuerStock Option (Right to Buy) · Derivative	26,000	Not disclosed Strike: $5.59	Not disclosed	Disclosure SEC source: 0001209191-23-043423 · doc4.xml · derivative · entry 1 BERGER FRANKLIN M · CIK 0001273885 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,000 shares Expires 2031-06-27 F2 · price: On July 24, 2023, the option originally granted to the Reporting Person was amended to reduce the exercise price to $2.28 per share. All of the other terms of the option remain unchanged. F1 · derivative.exercise_date: Fully vested and exercisable. Read SEC document
June 16, 2023 Filed Jun 21, 2023 20:05 UTC	Atea Pharmaceuticals, Inc. AVIR · Entity 5580	GrantStock Option (Right to Buy) · Derivative	46,750	$0.00 Strike: $4.12	$0.00	Disclosure SEC source: 0000899243-23-016131 · doc4.xml · derivative · entry 2 BERGER FRANKLIN M · CIK 0001273885 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,750 Underlying: Common Stock · 46,750 shares Expires 2033-06-15 F3 · derivative.exercise_date: The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 16, 2023, such that the option shall be fully vested on the first anniversary of the date of grant, subject to the Reporting Person's continued service through each such vesting date. Read SEC document
June 16, 2023 Filed Jun 21, 2023 20:05 UTC	Atea Pharmaceuticals, Inc. AVIR · Entity 5580	GrantRestricted Stock Units · Derivative	33,150	$0.00	$0.00	Disclosure SEC source: 0000899243-23-016131 · doc4.xml · derivative · entry 1 BERGER FRANKLIN M · CIK 0001273885 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,150 Underlying: Common Stock · 33,150 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date. F2 · derivative.expiration_date: The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document
June 15, 2023 Filed Jun 16, 2023 20:38 UTC	Kezar Life Sciences, Inc. KZR · Entity 12111	GrantStock Option (right to buy) · Derivative	35,000	$0.00 Strike: $2.64	$0.00	Disclosure SEC source: 0001209191-23-037931 · doc4.xml · derivative · entry 1 BERGER FRANKLIN M · CIK 0001273885 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2033-06-14 F1 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option shall vest on 6/15/2024, subject to Reporting Person continuing to provide service through such date. Read SEC document
June 13, 2023 Filed Jun 15, 2023 22:05 UTC	Atreca, Inc. BCEL · Entity 91940	GrantStock Option (right to buy) · Derivative	12,000	$0.00 Strike: $1.18	$0.00	Disclosure SEC source: 0001209191-23-037516 · doc4.xml · derivative · entry 1 BERGER FRANKLIN M · CIK 0001273885 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Class A Common Stock · 12,000 shares Expires 2023-06-12 F1 · derivative.exercise_date: The option vests upon the earlier of the one-year anniversary of the date of grant or the day prior to the next Annual Meeting of Stockholders occurring after the grant date, subject to the non-employee director's continuous service on each applicable vesting date. All unvested options will vest in full immediately prior to a change in control (as defined in the Company's 2019 Equity Incentive Plan), subject to the non-employee director's continuous service as of immediately prior to the closing of such change in control. Read SEC document
December 21, 2022 Filed Jan 5, 2023 15:41 UTC	ESSA Pharma Inc. EPIX · Entity 15763	SaleCommon Shares	34,334	$2.42	$83,088.28	Disclosure SEC source: 0000899243-23-000914 · doc4.xml · nonDerivative · entry 7 BERGER FRANKLIN M · CIK 0001273885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 684,404 Read SEC document
December 21, 2022 Filed Jan 5, 2023 15:41 UTC	ESSA Pharma Inc. EPIX · Entity 15763	SaleCommon Shares	37,889	$2.41	$91,312.49	Disclosure SEC source: 0000899243-23-000914 · doc4.xml · nonDerivative · entry 6 BERGER FRANKLIN M · CIK 0001273885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 718,738 Read SEC document
December 20, 2022 Filed Jan 5, 2023 15:41 UTC	ESSA Pharma Inc. EPIX · Entity 15763	SaleCommon Shares	43,617	$2.53	$110,351.01	Disclosure SEC source: 0000899243-23-000914 · doc4.xml · nonDerivative · entry 5 BERGER FRANKLIN M · CIK 0001273885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 756,627 Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.